Last reviewed · How we verify
Shaheed Mohtarma Benazir Bhutto Institue of Trauma — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
2 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Intravenous Dexmedetomidine infusion | Intravenous Dexmedetomidine infusion | marketed |
Therapeutic area mix
- Emergency Medicine · 1
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Centre Hospitalier Universitaire, Amiens · 2 shared drug classes
- Ain Shams University · 1 shared drug class
- Bagcilar Training and Research Hospital · 1 shared drug class
- Atlantic Health System · 1 shared drug class
- Aultman Health Foundation · 1 shared drug class
- B.P. Koirala Institute of Health Sciences · 1 shared drug class
- Aligarh Muslim University · 1 shared drug class
- Ain Shams Maternity Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shaheed Mohtarma Benazir Bhutto Institue of Trauma:
- Shaheed Mohtarma Benazir Bhutto Institue of Trauma pipeline updates — RSS
- Shaheed Mohtarma Benazir Bhutto Institue of Trauma pipeline updates — Atom
- Shaheed Mohtarma Benazir Bhutto Institue of Trauma pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shaheed Mohtarma Benazir Bhutto Institue of Trauma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shaheed-mohtarma-benazir-bhutto-institue-of-trauma. Accessed 2026-05-17.